Analysts show mixed responses to Modiv Industrial's latest performance. They've lowered revenue predictions and increased loss per share forecasts for next year. The company is anticipated to lag the industry, with revenues expected to shrink annually by 3.0% until 2024 end, against industry growth of 5.6%.
CEO Aaron Halfacre highlights strategy of offering monthly dividends, made possible by a robust dividend coverage ratio. Anticipation of receiving GIPR shares, to be distributed to Modiv's shareholders, exemplifies this approach.
Upgrades •$Ardagh Metal(AMBP.US)$: Barclays Upgrades to Overweight from Equalweight - PT $9 •$美國運通(AXP.US)$: Edward Jones Upgrades to Buy from Hold •$CrowdStrike(CRWD.US)$: Morgan Stanley Upgrades to Overweight from Equalweight - PT $215 (from $195) •$Lululemon Athletica(LULU.US)$: Bernstein Upgrades to Market Perform from Underperform - PT $300 (from $260) •$瑞思邁(RMD.US)$: RBC Upgrades to Outperform from Sector Perform - PT $244 (from $...
Gainers: •$Clovis Oncology(CLVS.US)$+40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial) •$Dare Bioscience(DARE.US)$+13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO) •$KULR Technology(KULR.US)$+9.5% (secured a battery sa...
Modiv Industrial股票討論區
專欄Top upgrades and downgrades on 6/6
• $Ardagh Metal(AMBP.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $9
• $美國運通(AXP.US)$ : Edward Jones Upgrades to Buy from Hold
• $CrowdStrike(CRWD.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $215 (from $195)
• $Lululemon Athletica(LULU.US)$ : Bernstein Upgrades to Market Perform from Underperform - PT $300 (from $260)
• $瑞思邁(RMD.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $244 (from $...
專欄Today's pre-market stock movers: CLVS, PATH, DARE and more
• $Clovis Oncology(CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US)$ +9.5% (secured a battery sa...
暫無評論